Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 178

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 178
---
 laws also mandate proficiency testing
for laboratories licensed under the laws of each respective State regardless of whether such laboratories are located in California, Maryland,
New York or Rhode Island. If DiamiR is unable to obtain or maintain its CLIA certificate for its laboratory, whether as a result
of revocation, suspension or limitation, DiamiR would no longer be able to perform its current clinical services on samples from those
States, which could have a material adverse effect on its business, financial condition and results of operations. If DiamiR were to lose
its licenses issued by States where it is required to hold licenses, if such licenses expired or were not renewed, or if it failed to
obtain and maintain a State license that it is required to hold, it may be subject to significant fines, penalties and liability, and
may be forced to cease testing (if Connecticut) or cease testing specimens from those States (if California, New York, Maryland,
or Rhode Island), which could have a material adverse effect on DiamiR’s business, financial condition and results of operations.
New molecular diagnostic tests DiamiR may develop may be subject to new requirements by governmental bodies, including state governments,
and DiamiR may not be able to offer its new molecular diagnostic tests in such jurisdictions until such requirements are met.

<div align='center'>94</div>

Risks Related to DiamiR’s Intellectual Property and Product Liability

DiamiR may be unable to protect or obtain proprietary rights.

In developing, manufacturing and using its products, DiamiR employs
a variety of proprietary and patented technologies. DiamiR cannot provide any assurance that the patent and pending patent applications
that it currently owns provide (or will provide when issued) protection from competitive threats or from patent challenges. In addition,
DiamiR cannot provide any assurances that it will be successful in obtaining and maintaining its patents or in obtaining licenses to proprietary
or patented technologies of others in the future.

Furthermore, effective intellectual property protection may not be
available in every country in which DiamiR operates or intends to operate its business in. There can be no assurance that others will
not offer technologies, functions, features, or concepts that are substantially similar to DiamiR’s and compete with DiamiR’s
business, or copy or otherwise obtain, disclose and/or use DiamiR’s brand, platform features, design elements, DiamiR’s algorithms
and capabilities or other information that DiamiR considers proprietary without authorization. DiamiR may be unable to